|
C17ORF80 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.62747593179802E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.64968039229052E-12 |
| Normal-vs-Stage2 |
1.40970000117591E-08 |
| Normal-vs-Stage3 |
1.62447832963153E-12 |
| Normal-vs-Stage4 |
1.62447832963153E-12 |
| Stage1-vs-Stage2 |
6.934100E-02 |
| Stage1-vs-Stage3 |
3.322900E-03 |
| Stage1-vs-Stage4 |
1.440110E-04 |
| Stage2-vs-Stage3 |
2.815000E-04 |
| Stage2-vs-Stage4 |
8.06060000000386E-05 |
| Stage3-vs-Stage4 |
3.366400E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
7.7715611723761E-16 |
| Normal-vs-AfricanAmerican |
6.2482999885205E-09 |
| Normal-vs-Asian |
6.56708021296026E-12 |
| Caucasian-vs-AfricanAmerican |
8.380400E-01 |
| Caucasian-vs-Asian |
2.575000E-01 |
| AfricanAmerican-vs-Asian |
5.685800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.6251444634463E-12 |
| Normal-vs-Female |
1.63036251166204E-12 |
| Male-vs-Female |
2.986000E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.64124269730337E-12 |
| Normal-vs-Age(41-60Yrs) |
<1E-12 |
| Normal-vs-Age(61-80Yrs) |
1.62458935193399E-12 |
| Normal-vs-Age(81-100Yrs) |
5.85749999999496E-05 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
7.105800E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.066030E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
6.106200E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
2.090200E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
7.378800E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
9.290000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
8.09839999948991E-07 |
| Classical-VS-Follicular |
8.915300E-03 |
| Classical-VS-Other |
8.099000E-01 |
| Classical-VS-Normal |
1.65645275274073E-12 |
| Tall-VS-Follicular |
8.87039997010675E-09 |
| Tall-VS-Other |
1.729830E-01 |
| Tall-VS-Normal |
<1E-12 |
| Follicular-VS-Other |
3.250000E-01 |
| Follicular-VS-Normal |
2.50860443529177E-11 |
| Other-VS-Normal |
2.821200E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.11022302462516E-16 |
| Normal-vs-N1 |
9.99200722162641E-16 |
| N0-vs-N1 |
1.380410E-02 |
|
|
